Dual therapy trial using esomeprazole and amoxicillin as third-line rescue therapy for Helicobacter pylori infection

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background/Aims: The purpose of this study was to evaluate the efficacy and tolerability of dual therapy consisting of esomeprazole and amoxicillin as a rescue therapy for Helicobacter pylori infection. Methods: From December 2009 to August 2010, 21 patients who experienced two consecutive eradication failures were included. They received esomeprazole (40 mg, b.i.d.) and amoxicillin (1,000 mg, b.i.d.) for 14 days as a third eradication regimen. Compliance and side effects were determined from an interview. H. pylori status was evaluated using the 13C urea breath test at least 6 weeks after treatment. Results: The mean age of the patients was 59 years and included 52% males. Indications for treatment were functional dyspepsia (61.9%), peptic ulcer disease (28.6%), and gastric adenoma (9.5%). H. pylori was eradicated in 14 of 21 (66.7%) patients. Minor side effects were reported in three of the 21 patients (14.3%). These side effects consisted mainly of nausea and epigastric discomfort. Conclusions: A 2-week course of dual therapy failed to show satisfactory results in third-line H. pylori eradication, but it was very safe and tolerable. Therefore, dual therapy constitutes an encouraging empirical strategy for the elderly and infirm patients with multiple previous eradication failures.

Original languageEnglish
Pages (from-to)33-37
Number of pages5
JournalClinical Endoscopy
Volume44
Issue number1
DOIs
StatePublished - 1 Dec 2011

Fingerprint

Esomeprazole
Amoxicillin
Helicobacter Infections
Helicobacter pylori
Therapeutics
Stomach Diseases
Breath Tests
Dyspepsia
Peptic Ulcer
varespladib methyl
Adenoma
Nausea
Compliance
Urea
Interviews

Keywords

  • Amoxicillin
  • Helicobacter pylori
  • Proton pump inhibitor
  • Therapy

Cite this

@article{b17b99d227ca40e585030f4695f08e00,
title = "Dual therapy trial using esomeprazole and amoxicillin as third-line rescue therapy for Helicobacter pylori infection",
abstract = "Background/Aims: The purpose of this study was to evaluate the efficacy and tolerability of dual therapy consisting of esomeprazole and amoxicillin as a rescue therapy for Helicobacter pylori infection. Methods: From December 2009 to August 2010, 21 patients who experienced two consecutive eradication failures were included. They received esomeprazole (40 mg, b.i.d.) and amoxicillin (1,000 mg, b.i.d.) for 14 days as a third eradication regimen. Compliance and side effects were determined from an interview. H. pylori status was evaluated using the 13C urea breath test at least 6 weeks after treatment. Results: The mean age of the patients was 59 years and included 52{\%} males. Indications for treatment were functional dyspepsia (61.9{\%}), peptic ulcer disease (28.6{\%}), and gastric adenoma (9.5{\%}). H. pylori was eradicated in 14 of 21 (66.7{\%}) patients. Minor side effects were reported in three of the 21 patients (14.3{\%}). These side effects consisted mainly of nausea and epigastric discomfort. Conclusions: A 2-week course of dual therapy failed to show satisfactory results in third-line H. pylori eradication, but it was very safe and tolerable. Therefore, dual therapy constitutes an encouraging empirical strategy for the elderly and infirm patients with multiple previous eradication failures.",
keywords = "Amoxicillin, Helicobacter pylori, Proton pump inhibitor, Therapy",
author = "Park, {Hyun Kyung} and Lee, {Dong Ho} and Seungchul Suh and Seo, {Pyoung Ju} and Nayoung Kim and Jeong, {Sook Hyang} and Kim, {Jin Wook} and Hwang, {Jin Hyeok} and Park, {Young Soo} and Lee, {Sang Hyub} and Shin, {Cheol Min}",
year = "2011",
month = "12",
day = "1",
doi = "10.5946/ce.2011.44.1.33",
language = "English",
volume = "44",
pages = "33--37",
journal = "Clinical Endoscopy",
issn = "2234-2400",
publisher = "Korean Society of Gastrointestinal Endoscopy",
number = "1",

}

TY - JOUR

T1 - Dual therapy trial using esomeprazole and amoxicillin as third-line rescue therapy for Helicobacter pylori infection

AU - Park, Hyun Kyung

AU - Lee, Dong Ho

AU - Suh, Seungchul

AU - Seo, Pyoung Ju

AU - Kim, Nayoung

AU - Jeong, Sook Hyang

AU - Kim, Jin Wook

AU - Hwang, Jin Hyeok

AU - Park, Young Soo

AU - Lee, Sang Hyub

AU - Shin, Cheol Min

PY - 2011/12/1

Y1 - 2011/12/1

N2 - Background/Aims: The purpose of this study was to evaluate the efficacy and tolerability of dual therapy consisting of esomeprazole and amoxicillin as a rescue therapy for Helicobacter pylori infection. Methods: From December 2009 to August 2010, 21 patients who experienced two consecutive eradication failures were included. They received esomeprazole (40 mg, b.i.d.) and amoxicillin (1,000 mg, b.i.d.) for 14 days as a third eradication regimen. Compliance and side effects were determined from an interview. H. pylori status was evaluated using the 13C urea breath test at least 6 weeks after treatment. Results: The mean age of the patients was 59 years and included 52% males. Indications for treatment were functional dyspepsia (61.9%), peptic ulcer disease (28.6%), and gastric adenoma (9.5%). H. pylori was eradicated in 14 of 21 (66.7%) patients. Minor side effects were reported in three of the 21 patients (14.3%). These side effects consisted mainly of nausea and epigastric discomfort. Conclusions: A 2-week course of dual therapy failed to show satisfactory results in third-line H. pylori eradication, but it was very safe and tolerable. Therefore, dual therapy constitutes an encouraging empirical strategy for the elderly and infirm patients with multiple previous eradication failures.

AB - Background/Aims: The purpose of this study was to evaluate the efficacy and tolerability of dual therapy consisting of esomeprazole and amoxicillin as a rescue therapy for Helicobacter pylori infection. Methods: From December 2009 to August 2010, 21 patients who experienced two consecutive eradication failures were included. They received esomeprazole (40 mg, b.i.d.) and amoxicillin (1,000 mg, b.i.d.) for 14 days as a third eradication regimen. Compliance and side effects were determined from an interview. H. pylori status was evaluated using the 13C urea breath test at least 6 weeks after treatment. Results: The mean age of the patients was 59 years and included 52% males. Indications for treatment were functional dyspepsia (61.9%), peptic ulcer disease (28.6%), and gastric adenoma (9.5%). H. pylori was eradicated in 14 of 21 (66.7%) patients. Minor side effects were reported in three of the 21 patients (14.3%). These side effects consisted mainly of nausea and epigastric discomfort. Conclusions: A 2-week course of dual therapy failed to show satisfactory results in third-line H. pylori eradication, but it was very safe and tolerable. Therefore, dual therapy constitutes an encouraging empirical strategy for the elderly and infirm patients with multiple previous eradication failures.

KW - Amoxicillin

KW - Helicobacter pylori

KW - Proton pump inhibitor

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=84878681135&partnerID=8YFLogxK

U2 - 10.5946/ce.2011.44.1.33

DO - 10.5946/ce.2011.44.1.33

M3 - Article

C2 - 22741110

AN - SCOPUS:84878681135

VL - 44

SP - 33

EP - 37

JO - Clinical Endoscopy

JF - Clinical Endoscopy

SN - 2234-2400

IS - 1

ER -